Potentiating cancer vaccine efficacy in liver cancer

Tagliamonte, Maria; Petrizzo, Annacarmen; Mauriello, Angela; Tornesello, Maria Lina; Buonaguro, Franco M.; Buonaguro, Luigi

doi:10.1080/2162402x.2018.1488564

Cited by 30 publications

(21 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although vaccines were traditionally considered as a stand-alone therapy, it is now clear that they should be part of combinatorial strategies with ICIs or ACT. The immunosuppressive TME impairs T cell activity, suggesting that combinations of ICIs might block these factors and facilitate the effector function of anti-tumour lymphocytes 186 .…”

Section: Other Hcc Immunotherapiesmentioning

confidence: 99%

Advances in immunotherapy for hepatocellular carcinoma

Sangro

Sarobe

Hervás-Stubbs

et al. 2021

Nat Rev Gastroenterol Hepatol

856

571

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated by the immune system. Systemic therapy is used in the advanced stage and until 2017 consisted only of antiangiogenic tyrosine kinase inhibitors (TKIs). Immunotherapy with checkpoint inhibitors has shown strong anti-tumour activity in a subset of patients and the combination of the anti-PDL1 antibody atezolizumab and the VEGF-neutralizing antibody bevacizumab has or will soon become the standard of care as a first-line therapy for HCC, whereas the anti-PD1 agents nivolumab and pembrolizumab are used after TKIs in several regions. Other immune strategies such as adoptive T-cell transfer, vaccination or virotherapy have not yet demonstrated consistent clinical activity. Major unmet challenges in HCC checkpoint immunotherapy are the discovery and validation of predictive biomarkers, advancing treatment to earlier stages of the disease, applying the treatment to patients with liver dysfunction and the discovery of more effective combinatorial or sequential approaches. Combinations with other systemic or local treatments are perceived as the most promising opportunities in HCC and some are already under evaluation in large-scale clinical trials. This Review provides up-to-date information on the best use of currently available immunotherapies in HCC and the therapeutic strategies under development.

show abstract

Section: Other Hcc Immunotherapiesmentioning

confidence: 99%

Advances in immunotherapy for hepatocellular carcinoma

Sangro

Sarobe

Hervás-Stubbs

et al. 2021

Nat Rev Gastroenterol Hepatol

856

571

View full text Add to dashboard Cite

show abstract

“…Furthermore, other modalities of immunotherapy are under evaluation in HCC, such as peptide and dendritic cell-based vaccines, oncolytic viruses and chimeric antigen receptor (CAR) T-cell therapies. Peptide vaccines based on HCC-associated antigens (AFP, glypican-3, telomerase reverse transcriptase) have shown limited efficacy although inducing T-cell-specific responses [47]. Dendritic cell-based vaccines have been evaluated in many small studies in HCC with encouraging results providing hope for further development [48].…”

Section: Combinations Of Icis and Other Immunotherapiesmentioning

confidence: 99%

Immune Therapy for Liver Cancers

Hilmi

Vienot

Rousseau

et al. 2019

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) display a poor prognosis with 5-year overall survival rates around 15%, all stages taken together. These primary liver malignancies are often diagnosed at advanced stages where therapeutic options are limited. Recently, immune therapy has opened new opportunities in oncology. Based on their high programmed death-ligand 1 expression and tumor-infiltrating lymphocytes, HCC and BTC are theoretically good candidates for immune checkpoint blockade. However, clinical activity of single agent immunotherapy appears limited to a subset of patients, which is still ill-defined, and combinations are under investigation. In this review, we provide an overview of (i) the biological rationale for immunotherapies in HCC and BTC, (ii) the current state of their clinical development, and (iii) the predictive value of immune signatures for both clinical outcome and response to these therapies.

show abstract

“…Likewise, in the case of HCC, combinatorial protocols (e.g., TACE plus anti-CTLA-4) [ 32 ] have been reported and an important number of combinations are under investigation [ 33 ]. However, in addition to these combinations, vaccination emerges as a highly specific strategy to enhance antitumor immunity against relevant antigens of choice [ 34 ]. With this purpose, we have tested a combinatorial protocol based on the administration of a CIRP-based vaccine plus ICPI anti-CTLA-4 and anti-PD-1.…”

Section: Discussionmentioning

confidence: 99%

Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma

Silva

Egea

Villanueva

et al. 2020

Cancers

View full text Add to dashboard Cite

Therapies based on immune checkpoint inhibitors (ICPI) have yielded promising albeit limited results in patients with hepatocellular carcinoma (HCC). Vaccines have been proposed as combination partners to enhance response rates to ICPI. Thus, we analyzed the combined effect of a vaccine based on the TLR4 ligand cold-inducible RNA binding protein (CIRP) plus ICPI. Mice were immunized with vaccines containing ovalbumin linked to CIRP (OVA-CIRP), with or without ICPI, and antigen-specific responses and therapeutic efficacy were tested in subcutaneous and orthotopic mouse models of liver cancer. OVA-CIRP elicited polyepitopic T-cell responses, which were further enhanced when combined with ICPI (anti-PD-1 and anti-CTLA-4). Combination of OVA-CIRP with ICPI enhanced ICPI-induced therapeutic responses when tested in subcutaneous and intrahepatic B16-OVA tumors, as well as in the orthotopic PM299L HCC model. This effect was associated with higher OVA-specific T-cell responses in the periphery, although many tumor-infiltrating lymphocytes still displayed an exhausted phenotype. Finally, a new vaccine containing human glypican-3 linked to CIRP (GPC3-CIRP) induced clear responses in humanized HLA-A2.01 transgenic mice, which increased upon combination with ICPI. Therefore, CIRP-based vaccines may generate anti-tumor immunity to enhance ICPI efficacy in HCC, although blockade of additional checkpoint molecules and immunosuppressive targets should be also considered.

show abstract

Potentiating cancer vaccine efficacy in liver cancer

Cited by 30 publications

References 96 publications

Advances in immunotherapy for hepatocellular carcinoma

Advances in immunotherapy for hepatocellular carcinoma

Immune Therapy for Liver Cancers

Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma

Contact Info

Product

Resources

About